Clinical trials: sponsored by University Hospital Heidelberg
Glioblastoma, Adult
NCT Neuro Master Match - N²M² (NOA-20)
The objective of N²M² is the improvement of overall survival of patients with glioblastoma with an unmethylated MGMT promoter based on molecular characterization and use of targeted compounds in a modern trial design.
- Trial name
- N²M² (NCT03158389)
- Testing
- APG101, Alectinib, Idasanutlin
- Where
- 13 sites in Germany
- Volunteers
- 228 people
- Sponsor
- University Hospital Heidelberg
Premature Treatment Termination, Dropout Prediction
Predicting Premature Treatment Termination in Inpatient Psychotherapy: A Machine Learning Approach
The study aims to develop a prediction model of premature treatment termination in psychosomatic hospitals using a machine learning approach.
- Conditions
- Premature Treatment Termination, Dropout Prediction, Inpatient Psychotherapy, Machine Learning
- Trial name
- NCT06042595
- Testing
- Psychotherapy
- Volunteers
- 2,023 people
- Sponsor
- University Hospital Heidelberg
Ischemic Stroke, Intracerebral Hemorrhage
Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime
The Registry of Acute Stroke Under Novel Oral Anticoagulants-Prime (RASUNOA-Prime), an investigator-initiated study, is a German multicenter, prospective, observational registry.
- Conditions
- Ischemic Stroke, Intracerebral Hemorrhage, Oral Anticoagulation, Cardiovascular Diseases
- Trial name
- RASUNOA-Prime (NCT02533960)
- Testing
- not applicable (observational study)
- Where
- Germany
- Volunteers
- 3,832 people
- Sponsor
- University Hospital Heidelberg
PD-1 Antibodies, Exercise
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
Checkpoint inhibitors like the PD-1 antibodies Pembrolizumab and Nivolumab represent standard of care for patients with metastasized melanoma.
- Conditions
- PD-1 Antibodies, Exercise, Melanoma
- Trial name
- Sportivumab (NCT03171064)
- Testing
- Resistance and Endurance Exercise
- Where
- Germany
- Volunteers
- 39 people
- Sponsor
- University Hospital Heidelberg
Partial Edentulism
Clinical Performance of Long-span Fixed Partial Dentures
Tooth-coloured fixed restorations are becoming increasingly popular with patients and dentists. If high-strength all-ceramics such as zirconia are used as the restoration material, a maximum of two adjacent missing teeth can be…
- Trial name
- NCT04166695
- Testing
- Monolithic / facially veneered zirconia fixed partial denture, Completely veneered CoCr fixed partial denture
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- University Hospital Heidelberg
Chordoma
CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma
In chordoma cell lines and patient biopsies, the p16 (CDKN2A) tumor suppressor is consistently deleted. Thus, chordomas are an example of a tumor with universal activation of the cyclin-dependent kinases 4 and 6 (CDK4/6) pathway…
- Trial name
- NCT-PMO-1601 (NCT03110744)
- Testing
- Palbociclib
- Where
- 3 sites in Germany
- Volunteers
- 43 people
- Sponsor
- University Hospital Heidelberg
Acute Myeloid Leukemia
TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib
The long-term outcome of patients with acute myeloid leukemia (AML) remains poor, with less than 30% of patients achieving long lasting remission or cure.
- Trial name
- TEAM (NCT04173585)
- Testing
- Bortezomib, Gemtuzumab Ozogamicin
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University Hospital Heidelberg
Advanced Cancer
Decision Aid to Support Advanced Cancer Patients
To support advanced cancer patients, for whom standard therapy is no longer available, and their oncologists in therapy decisions, the investigators aim to develop a decision-making aid (DA) in a multi-phased bicentric study.
- Trial name
- PETUPAL (NCT04606238)
- Testing
- Decision Aid
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- University Hospital Heidelberg
Skin Ulcer, Buruli Ulcer
Treat Early and Broad: Thermotherapy of Buruli Ulcer Integrated Into WHO-recommended Wound Management in West Africa
The project rolls out combined innovative low-tech thermotherapy with heat packs and WHO recommended wound management in a Buruli ulcer (BU)-endemic district of West Africa.
- Conditions
- Skin Ulcer, Buruli Ulcer, Nontuberculous Mycobacteria
- Trial name
- WOUNDCARE (NCT03957447)
- Testing
- thermotherapy (application of heat): This part of the trial is on hold due to the Covid19-pandemia
- Where
- Côte d’Ivoire
- Volunteers
- 5,000 people
- Sponsor
- University Hospital Heidelberg
Fatigue, Cancer
Exercise for Young Adults With Cancer
Over the past decade, importance of supportive care in cancer treatment of young cancer patients has increased. However, most common cancer-related side effects, such as physical deconditioning, psychological problems…
- Conditions
- Fatigue, Cancer, Physical Activity, Exercise
- Trial name
- YOUEX (NCT05613699)
- Testing
- Exercise - Social Media, Exercise - App, Exercise - closed to patients residence
- Where
- Germany
- Volunteers
- 106 people
- Sponsor
- University Hospital Heidelberg
Acute Ischemic Stroke
Individualized Blood Pressure Management During Endovascular Stroke Treatment
Optimal blood pressure management during endovascular treatment of acute ischemic stroke is not well established. Several retrospective data indicate, that there is a U-shaped relationship of admission blood pressure and…
- Trial name
- INDIVIDUATE (NCT04578288)
- Testing
- INDIVIDUALIZED BLOOD PRESSURE MANAGEMENT DURING ENDOVASCULAR TREATMENT OF ACUTE ISCHEMIC STROKE UNDER PROCEDURAL SEDATION
- Where
- Germany
- Volunteers
- 250 people
- Sponsor
- University Hospital Heidelberg
Patient Decision Aid, Treatment As Usual
Shared Decision Making on Immunotherapy in Oncology
Patients with advanced melanoma are confronted with a serious treatment decision. The current guideline recommends considering the option of immunotherapy with checkpoint inhibitors.
- Trial name
- PEF-Immun (NCT04240717)
- Testing
- Patient Decision Aid
- Where
- 2 sites in Germany
- Volunteers
- 126 people
- Sponsor
- University Hospital Heidelberg
Hepatocellular Carcinoma
Carbon Ion Radiotherapy for Hepatocellular Carcinoma
Treatment options for patients with advanced hepatocellular carcinoma (HCC) are often limited. In most cases, they are not amenable to local therapies including surgery or radiofrequency ablation.
- Trial name
- PROMETHEUS-01 (NCT01167374)
- Testing
- Carbon Ion Radiotherapy
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- University Hospital Heidelberg
Cancer, Age <70
Geriatric-oncological Study on Quality of Life and Independence After Radiotherapy
Elderly patients * with multiple comorbidities are underrepresented in most radio-oncology studies. In times of individualized therapy and when weighing up oncological over- or under-therapy, this observational study is a step…
- Trial name
- GOLD-I (NCT05187845)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Heidelberg
Atrial Fibrillation
Implementation of the HELIOSTARTM in Real-world Clinical Practice at a High-volume Center
The HELIOSTARTM catheter (Biosense Webster) is a new technology for pulmonary vein isolation (PVI) in atrial fibrillation (AF), combining radiofrequency (RF)-ablation and 3D-mapping visualization with the concept of…
- Trial name
- NCT05603611
- Testing
- Pulmonary vein isolation
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- University Hospital Heidelberg
Atrial Fibrillation
Catheter Ablation for Atrial Fibrillation in Preserved Ejection Fraction
Atrial fibrillation (AF) displays high prevalence in heart failure with preserved ejection fraction (HF-PEF) and compromises prognosis of affected patients.
- Trial name
- AFFECT (NCT04317911)
- Testing
- Catheter Ablation
- Where
- Germany
- Volunteers
- 102 people
- Sponsor
- University Hospital Heidelberg
Inpatient Psychotherapy, Self Efficacy
Agentic Self-view as Common Factor in Psychotherapy - Self-efficacy in the Treatment of Inpatients Over the Course of Time
The purpose of this study is to assess the development of self-efficacy over the course of psychotherapeutic inpatient treatment and to examine the interplay of symptom severity with group cohesion and positive self-view…
- Conditions
- Inpatient Psychotherapy, Self Efficacy, Group Cohesion, Treatment Outcome
- Trial name
- AGENTIC (NCT05594160)
- Testing
- Psychotherapy
- Volunteers
- 1,544 people
- Sponsor
- University Hospital Heidelberg
Leukemia, Myeloid, Acute
Evaluation of Measurable Residual Disease in Patients With Acute Myeloid Leukemia as Surrogate Endpoint for Survival
Objectives To demonstrate that measurable residual disease assessed by multiparameter flow cytometry during intensive treatment is a surrogate for overall survival and thus an early read-out for drug efficacy Study design…
- Trial name
- PERDAM (NCT03549351)
- Testing
- Measurable residual disease measured by flow cytometry
- Where
- Germany
- Volunteers
- 51 people
- Sponsor
- University Hospital Heidelberg
Acute Myeloid Leukemia
Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)
The study is a randomized phase III trial with a 2x2 factorial design with measurable residual disease and event-free survival as primary endpoints, respectively.
- Trial name
- GnG (NCT04093505)
- Testing
- Gemtuzumab Ozogamicin 147, Gemtuzumab Ozogamicin 1, Glasdegib
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- University Hospital Heidelberg
Metastatic Colorectal Cancer, MSS
Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC
This is a monocentric, single arm, prospective, open-label trial of a combination treatment consisting of pembrolizumab and maraviroc in previously treated subjects who have refractory microsatellite stable (MSS) metastatic…
- Trial name
- PICCASSO (NCT03274804)
- Testing
- Pembrolizumab, Maraviroc
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Heidelberg